Table 1.

Clinicopathologic characteristics in each cohort and in the total material

Training cohort Tromso, Norway (UNN)Validation cohort Bodo, Norway (NH)Validation cohort Oslo, Norway (OUS)Validation cohort Odense, DenmarkTotal cohort
Number of patients155169295178797
Time of inclusion1990–20051990–20052006–20111992–19991990–2011
Median age in years66.6 (range, 38.8–84.7)67.3 (range, 27.5–82.1)66.5 (range, 39.1–84.1)64.1 (range, 39.4–82.4)65.2 (range, 27.5–84.7)
Last follow-upJanuary 2011January 2011March 2014January 2010January 2010–March 2014
Median follow-up time of the survivors in months110.7 (range, 76.3–222.2)102.8 (range, 72.9–234.0)52.4 (range, 34.9–99.4)161.7 (range, 120.6–210.8)65.5 (range, 34.9–34.0)
Scoring systemExploratoryPredefinedPredefinedPredefinedPredefined
Different cutoff system tested, and both average and maximum score evaluated. Optimal prognostic impact cutoff defined and used in all cohorts.Maximum scoreMaximum scoreMaximum scoreMaximum score
Low density: ≤25%Low density: ≤25%Low density: ≤25%Low density: ≤25%
Intermediate density: >25%–≤ 50%Intermediate density: >25%–≤ 50%Intermediate density: >25%–≤50%Intermediate density: >25%–≤ 50%
High density: >50%High density: >50%High density: >50%High density: >50%
EndpointsDSS, DFS, OSDSS, DFS, OSDSS, DFS, OSDSS, DFS, OSDSS, DFS, OS
TMA core size0.6 mm0.6 mm1.0 mm1.0 mm0.6–1.0 mm
CD8+ IHC stainingClinical routineClinical routineClinical routineClinical routineClinical routine
Number of cores from each patientsFourFourVariable, minimum of threeFour, two from central and two from invasive marginsVariable, but at least potentially three evaluable from each patient.
TMA thickness4 μm4 μm4 μm4 μm4 μm
Distribution stromal CD8+ density score (%) 1: low, 2: intermediate, 3: high1: 35 (23)1: 47 (28)1: 77 (27)1: 50 (28)1: 209 (27)
2: 80 (52)2: 90 (53)2: 156 (53)2: 77 (43)2: 403 (52)
3: 39 (25)3: 29 (17)3: 56 (19)3: 47 (26)3: 171 (22)
Missing: 1Missing: 3Missing: 6Missing: 4Missing: 14